What is Product Quality Review in GMP?

Short answer: Product Quality Review (PQR) is the periodic, usually annual, evaluation of a medicinal product and the processes used to manufacture and control it. It brings together quality, manufacturing and regulatory data to confirm that the process remains in control, identify trends and determine whether CAPA, change, revalidation or other improvement is needed.

In some regulatory systems the related term Annual Product Review (APR) is used. The detailed requirements differ by jurisdiction, but both approaches test whether product and process performance remain suitable rather than merely summarising how many batches were made.

How often should a PQR be completed?

EU GMP expects regular periodic or rolling reviews, and EMA inspector guidance states that the product review is expected annually. A justified review window can reflect manufacturing or campaign duration, but the timeframe and cut-off rules should be defined in an approved procedure.

A review is still needed when no batches were manufactured during the period. It should consider relevant stability data, returns, complaints, recalls, deviations, validation activity, regulatory changes and the previous PQR. Low manufacturing volume is not a reason to omit the review; it affects how evidence and trends are interpreted.

What should the scope cover?

Starting materials and packaging materials, especially those from new or changed sources.
Critical in-process controls, finished-product results and meaningful process-performance data.
Batches that failed specification and the associated investigations.
Significant deviations, non-conformances, investigations and the effectiveness of CAPA.
Changes to processes, analytical methods, equipment, facilities, utilities, systems or suppliers.
Marketing-authorisation variations submitted, granted, refused or still pending.
Ongoing stability results, adverse trends and any proposed shelf-life or storage change.
Quality-related returns, complaints, recalls, defects and field information.
Previous corrective actions, commitments and the effectiveness of completed actions.
The qualification status of relevant equipment and utilities, including HVAC, water and gases.
Technical or quality agreements and the performance of outsourced activities.

The exact data set should be product- and process-specific. A list of required inputs should define sources, owners, cut-off dates and rules for incomplete or late data so that the review is reproducible and auditable.

How should the data be analysed?

A PQR should test trends, variability and relationships rather than copy tables into a report. Use appropriate statistical and graphical methods where they improve understanding. Consider batch-to-batch variation, shifts over time, recurring exceptions, changes before and after an intervention, and whether process capability remains suitable for registered requirements.

Data quality matters. Confirm definitions, units, denominators, excluded batches, duplicate events and the source of manually compiled data. A favourable average can hide special-cause variation, a deteriorating sub-group or repeated events across several systems.

Can products be grouped?

Product grouping may be appropriate where the scientific and technical rationale is documented and the grouped products genuinely share relevant materials, formulation, equipment, process, control strategy or risk. Grouping should not dilute product-specific signals or replace a review of data that are unique to an individual marketing authorisation.

The rationale, boundaries and representative products should be approved. Reassess the grouping when formulations, sites, equipment, processes or risks change. Where only a limited number of batches exist, use prior periods and supporting knowledge carefully without presenting sparse data as a robust trend.

What matters for sterile and aseptic products?

For sterile manufacture, the PQR should connect product performance with the contamination control strategy and the validated state. Relevant evidence may include environmental and personnel monitoring, process simulation, sterilisation or depyrogenation performance, bioburden, filter integrity, utility trends, interventions, sterility-test investigations, container-closure integrity and critical facility or equipment changes.

The review should not treat these data streams in isolation. For example, an increase in interventions, recurring environmental-monitoring excursions and adverse media-fill observations may collectively show a weaker control state even if released batches met specification.

Who prepares and approves the review?

Responsibilities should be defined between the manufacturer, marketing-authorisation holder and any contract sites. Manufacturing, Quality Control, Quality Assurance, Regulatory Affairs, Engineering, Validation, Supply Chain and other specialists may supply or interpret inputs, but Quality should provide independent oversight and ensure that conclusions are supported.

Where the MAH and manufacturer are different organisations, the relevant technical agreement should define data exchange, review, assessment and follow-up. Each party must have enough information to meet its responsibilities; fragmented ownership is not a justification for an incomplete PQR.

What decisions should the PQR produce?

Whether the process and control strategy remain capable and in a state of control.
Whether registered specifications, in-process controls or monitoring remain appropriate.
Whether CAPA, change control, revalidation or regulatory variation is required.
Whether recurring complaints, deviations or failures reveal a systemic issue.
Whether supplier, outsourced-activity or agreement controls need improvement.
Which opportunities for continual improvement should enter the Pharmaceutical Quality System.
Named owners, due dates, interim controls and escalation criteria for follow-up actions.

Conclusions should be explicit. Statements such as “no significant trend” should be supported by the data, method and acceptance rationale. Where evidence is incomplete, record the limitation, potential risk and plan to obtain the missing information.

How should follow-up be controlled?

PQR actions should enter the site's normal CAPA, change-control, validation or regulatory systems rather than remain in an isolated spreadsheet. Risk determines priority, but delayed actions need continued oversight and, where appropriate, interim controls.

The next PQR should review the status and effectiveness of previous actions. Management review should receive significant, recurring or cross-product themes, resource constraints and evidence that the review programme itself is functioning as intended.

Common weaknesses

Treating the PQR as a data compilation exercise with no meaningful evaluation.
Using inconsistent cut-off dates, definitions or denominators across departments.
Reporting batch results without testing trends, variability or process capability.
Excluding rejected, cancelled, reworked or validation batches without justification.
Failing to connect deviations, complaints, stability, validation and change data.
Weak coordination between the manufacturer, MAH and outsourced sites.
Generic conclusions that are not traceable to evidence.
Actions remaining in the PQR instead of governed quality-system records.
Failure to review previous actions and demonstrate effectiveness.
Late approval that makes the review too old to support timely decisions.

Questions to ask internally

Does the review include every authorised product and the correct reporting period?
Can every figure be traced to a controlled source and defined calculation?
Have we assessed trends, variability and relationships rather than only totals?
Are low-volume and grouped products supported by a scientific rationale?
Do sterile-product data connect to the contamination control strategy?
Are manufacturer, MAH and contract-site responsibilities clear?
Have conclusions produced governed actions with owners and due dates?
Did the last PQR's actions improve product or process control?

Official reference points

EU GMP Guide, Chapter 1 describes the expected content of regular product quality reviews and requires evaluation of results to determine whether CAPA or revalidation should be undertaken. The EMA GMP and GDP questions and answers confirms the expected annual frequency and explains that a review is still required when no manufacturing occurred.

How W2 can help

W2 Cleanroom Consulting can review PQR procedures, data maps, product-grouping rationale, trend analysis and follow-up governance. We can independently challenge whether conclusions are supported and help connect product review with validation, cleanroom performance, sterile processing, contamination control, complaints, CAPA and inspection readiness.

W2 provides independent consultancy support. The client remains responsible for licence obligations, Quality approval, QP or RP decisions, local Pharmaceutical Quality System control and regulatory correspondence.

Need help with Product Quality Review in a live GMP operation? Contact W2 Cleanroom Consulting at info@w2cleanrooms.com for independent review, inspection readiness or quality-system improvement support.

Prepared and reviewed by: W2 Cleanroom Consulting GMP team. Last reviewed: 24 July 2026.